Previous 10 | Next 10 |
home / stock / bioyf / bioyf news
BioSyent Inc. (BIOYF) Q3 2021 Earnings Conference Call November 18, 2021, 05:00 PM ET Company Participants René Goehrum - President and CEO Conference Call Participants Presentation René Goehrum Hello, and welcome to the BioSyent Inc. Q3 and YTD 2021 results presentation for the nin...
BioSyent (OTCPK:BIOYF): Q3 GAAP EPS of C$0.13. Revenue of C$6.69M (+15.9% Y/Y) beats by $1.25M. Press Release For further details see: BioSyent beats on revenue
BioSyent Inc. (BIOYF) Q2 2021 Earnings Conference Call August 25, 2021, 08:00 AM ET Company Participants René Goehrum - President and CEO Conference Call Participants Presentation René Goehrum Hello, and welcome to the BioSyent Q2 and First Half 2021 Results Presentation. My name is...
The following slide deck was published by BioSyent Inc. in conjunction with their 2021 Q1 earnings call. For further details see: BioSyent Inc. 2021 Q1 - Results - Earnings Call Presentation
BioSyent Inc. (BIOYF) Q1 2021 Earnings Conference Call May 27, 2021 08:00 ET Company Participants René Goehrum - President and Chief Executive Officer Presentation René Goehrum Hello and welcome to the BioSyent Inc. Q1 2021 Results Presentation. My name is René Goehrum, and I a...
Niche pharmaceutical player in Canada with a beautiful business model and a growing product portfolio. BioSyent has solid financials. At current prices, markets are ignoring the growth guided by the management and the catalyst ahead. BioSyent is undervalued at these prices. ...
BioSyent Pharma, a subsidiary of BioSyent ([[BIOYF]]) commenced the first shipments of Combogesic to Canadian wholesalers.Combogesic is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to m...
BioSyent Inc. (BIOYF) Q3 2020 Earnings Conference Call November 26, 2020 07:00 AM ET Company Participants René Goehrum - President & CEO Presentation René Goehrum Hello, and welcome to the BioSyent Q3 2020 Results Presentation. My name is René Goehrum, and I'm the President...
BioSyent ([[BIOYF]] -2.2%) introduces FeraMAX Pd, a new patented oral iron supplement formulation for the treatment of iron deficiency anemia.It has been developed by the company's subsidiary BioSyent Pharma in collaboration with its manufacturing partner to ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
News, Short Squeeze, Breakout and More Instantly...
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a Euro...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: Return on Equity for TTM March 31, 2024 was 21% as compared to 15% ...
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 20...